Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Starstone-Ovarian 301: BG-C9074 + Bevacizumab vs Bevacizumab in Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
NCT07811271Phase 3Not yet recruiting
- Sponsor
- BeOne Medicines
- Start
- Oct 2026
- Primary completion
- Nov 2029
01
Overview
A Phase 3 trial of BG-C9074 in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by BeOne Medicines. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
BG-C9074
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07811271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811271.